ImmuneRegen(r) BioSciences, Inc., Scottsdale, Ariz., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), has commenced a collaboration with DelSite Biotechnologies, Inc., a wholly owned subsidiary of Carrington Laboratories (CARN.OB), to develop a new vaccine adjuvant system that provides both immediate and sustained immunostimulation for more effective protection against a variety of transmittable pathogens.

With an initial focus on an influenza virus vaccine, the collaboration will determine if the combination of ImmuneRegen's vaccine adjuvant compound, Viprovex(r), and DelSite's unique adjuvant system, ...